STOCK TITAN
  1. Home
  2. Sec-filings
  3. ICCM
  4. [Form 3] IceCure Medical Ltd. Initial Statement of Beneficial Ownership

IceCure Medical (ICCM) CFO details shares, RSUs and options in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

IceCure Medical Ltd. Chief Financial Officer Ronen Tsimerman filed an initial Form 3 disclosing his equity holdings in the company. As of March 18, 2026, he holds 16,257 ordinary shares and 161,692 unvested restricted share units that vest over time under two RSU grants.

He also reports multiple share option awards over several years, covering tens of thousands of underlying ordinary shares at exercise prices ranging from $0.79 to $5.78 per share, with expiration dates extending from 2027 through 2034. Many of these options are fully vested, while some continue to vest in quarterly installments.

Positive

  • None.

Negative

  • None.
Insider Tsimerman Ronen
Role Chief Financial Officer
Type Security Shares Price Value
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Share option (right to buy) -- -- --
holding Ordinary shares -- -- --
Holdings After Transaction: Share option (right to buy) — 83,610 shares (Direct); Ordinary shares — 177,949 shares (Direct)
Footnotes (1)
  1. Represents (i) 16,257 ordinary shares, (ii) 106,102 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iii) 55,590 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026. A total of 95,555 options were granted on May 23, 2017, and vested in equal quarterly installments of 6.25% beginning May 1, 2017. As of March 18, 2026, 83,610 options are fully vested and 11,945 have been exercised into ordinary shares. The options were granted with an exercise price of NIS 2.448 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $0.79 per share. The options were granted on August 14, 2018, 25% of which vested on August 14, 2019, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 75,000 options are fully vested. The options were granted with an exercise price of NIS 6.472 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.09 per share. The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,549 options are fully vested. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share. The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 16,000 options are fully vested. The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share. The options were granted on August 30, 2020, 25% of which vested on August 30, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 28,833 options are fully vested. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,537 options are fully vested. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 121,002 options are fully vested. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 4,501 options are vested. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 36,634 options are vested. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 47,745 options are vested.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Tsimerman Ronen
(Last)(First)(Middle)
7 HA'ESHEL ST., PO BOX 3163
(Street)
CAESAREA3079504
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares177,949(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share option (right to buy) (2)05/23/2027Ordinary shares83,610$0.79(3)D
Share option (right to buy) (4)08/14/2028Ordinary shares75,000$2.09(5)D
Share option (right to buy) (6)03/28/2029Ordinary shares4,549$2.27(7)D
Share option (right to buy) (8)05/21/2029Ordinary shares16,000$1.79(9)D
Share option (right to buy) (10)08/30/2030Ordinary shares28,833$1.56(11)D
Share option (right to buy) (12)04/28/2031Ordinary shares1,537$5.78(13)D
Share option (right to buy) (14)01/12/2032Ordinary shares121,002$3.64(15)D
Share option (right to buy) (16)03/23/2032Ordinary shares4,802$2.84(17)D
Share option (right to buy) (18)02/19/2033Ordinary shares48,846$1.51(19)D
Share option (right to buy) (20)07/02/2034Ordinary shares127,322$0.92D
Explanation of Responses:
1. Represents (i) 16,257 ordinary shares, (ii) 106,102 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iii) 55,590 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.
2. A total of 95,555 options were granted on May 23, 2017, and vested in equal quarterly installments of 6.25% beginning May 1, 2017. As of March 18, 2026, 83,610 options are fully vested and 11,945 have been exercised into ordinary shares.
3. The options were granted with an exercise price of NIS 2.448 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $0.79 per share.
4. The options were granted on August 14, 2018, 25% of which vested on August 14, 2019, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 75,000 options are fully vested.
5. The options were granted with an exercise price of NIS 6.472 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.09 per share.
6. The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,549 options are fully vested.
7. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share.
8. The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 16,000 options are fully vested.
9. The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.
10. The options were granted on August 30, 2020, 25% of which vested on August 30, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 28,833 options are fully vested.
11. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share.
12. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,537 options are fully vested.
13. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share.
14. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 121,002 options are fully vested.
15. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.
16. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 4,501 options are vested.
17. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share.
18. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 36,634 options are vested.
19. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
20. The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 47,745 options are vested.
/s/ Ronen Tsimerman03/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the IceCure Medical (ICCM) Form 3 filing show for Ronen Tsimerman?

The Form 3 shows Ronen Tsimerman’s initial equity holdings in IceCure Medical. He reports ordinary shares, unvested restricted share units, and multiple share option grants with defined vesting schedules, exercise prices, and expiration dates as of March 18, 2026.

How many ordinary shares does IceCure Medical (ICCM) CFO Ronen Tsimerman hold?

Ronen Tsimerman holds 16,257 ordinary shares of IceCure Medical. A related disclosure explains this is part of a broader equity position that also includes unvested restricted share units and outstanding share options referenced in the same Form 3.

What RSU awards are disclosed for IceCure Medical (ICCM) CFO on Form 3?

The filing discloses 161,692 unvested RSUs for the CFO. These include 106,102 RSUs granted on July 2, 2024 and 55,590 RSUs granted on November 5, 2025, each vesting 25% on their first vesting date and 75% in 6.25% quarterly installments.

What option grants are reported for IceCure Medical (ICCM) CFO in this Form 3?

The CFO reports several share option grants with various exercise prices and terms. These cover underlying ordinary shares at exercise prices from $0.79 to $5.78 per share, with grant dates between 2017 and 2024 and expiration dates running from 2027 through 2034.

Are the IceCure Medical (ICCM) CFO’s options fully vested as of March 18, 2026?

Many, but not all, of the disclosed options are fully vested by March 18, 2026. Footnotes explain that several grants from 2017 to 2022 are fully vested, while more recent grants continue to vest in equal quarterly installments of 6.25% after the initial 25% vesting.

Does the IceCure Medical (ICCM) Form 3 show any insider buying or selling by the CFO?

The Form 3 does not report any new purchases or sales. It functions as an initial statement of beneficial ownership, listing existing ordinary shares, unvested RSUs, and option positions rather than current market transactions by the CFO.